Advertisement
Screener

Zentalis Pharmaceuticals, Inc. (ZNTL) Deferred Costs, Noncurrent

2.8 / 5 stars · 68/120 Roast Me

Zentalis Pharmaceuticals, Inc. Deferred Costs, Noncurrent

Zentalis Pharmaceuticals, Inc. (ZNTL) had Deferred Costs, Noncurrent of $716.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-12.

Discontinued › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:DeferredCosts · last filed 2021-08-12

  • 2021-06-30: Deferred Costs, Noncurrent $716.00K.
  • 2020-12-31: Deferred Costs, Noncurrent $0.00.
  • 2020-09-30: Deferred Costs, Noncurrent $0.00.
  • 2020-06-30: Deferred Costs, Noncurrent $0.00.
Period endDeferred Costs, Noncurrent
2021-06-30$716.00K
10-Q · filed 2021-08-12
2020-12-31$0.00
10-Q · filed 2021-08-12
2020-09-30$0.00
10-Q · filed 2020-11-09
2020-06-30$0.00
10-Q · filed 2020-08-13
2020-03-31$3.52M
10-Q · filed 2020-05-15
2019-12-31$841.00K
10-K · filed 2021-03-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Nkarta, Inc. (NKTX)United States$0.205B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B